Skip to search formSkip to main contentSkip to account menu

brivanib

Known as: (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol 
A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

12 relations

Broader (2)

AlanineTriazines

Narrower (3)

BMS 540215BMS 582664brivanib alaninate
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Systemic treatment.
2014
2014
Survival after sorafenib: expect the unexpected.
Review
2013
Review
2013
Emerging VEGF-receptor inhibitors for colorectal cancer
Introduction: Targeted agents have dramatically improved and enriched the therapeutical choices for patients with metastatic… 
2013
2013
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
This editorial accompanies three articles on three randomized, phase III trials of one disease: advanced hepatocellular carcinoma… 
2012
2012
Identification of the Oxidative and Conjugative Enzymes Involved in the Biotransformation of Brivanib
Brivanib alaninate, the l-alanine ester prodrug of brivanib, is currently being developed as an anticancer agent. In humans… 
2011
2011
Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.
10000 Background: Pts with sarcomas, a family of >70 types of cancer, have limited options once cytotoxic agents fail. Brivanib… 
Review
2011
Review
2011
Brivanib alaninate for cancer
Introduction: Angiogenesis inhibition represents a rational therapeutic strategy in the management of solid tumors. Brivanib is a… 
Review
2011
Review
2011
Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).
3079 Background: Brivanib (B) is an oral once daily selective dual inhibitor of FGF and VEGF signaling currently in phase III… 
Review
2010
Review
2010
Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan
Sorafenib, a molecular-targeted agent that inhibits tumor cell proliferation and angiogenesis by inhibiting RAF serine-threonine… 
2008
2008
A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced…
4111 Background: Brivanib alaninate (B) is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)